Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775521 | 0.86 | MAPK1 (0.49) | MAPK1KDM4EL3MBTL1CYP2C19LCK | |
| SCHEMBL16583134 | 0.83 | MAPK1 (0.44) | MAPK1KDM4EL3MBTL1CYP2C19LCK | |
| SCHEMBL68869 | 0.81 | MAPK1 (0.63) | MAPK1KDM4EL3MBTL1CYP2C19LCK | |
| SCHEMBL991402 | 0.80 | KDM4E (0.44) | MAPK1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL17635993 | 0.78 | CYP2C19 (0.32) | MAPK1CYP2C19 | |
| SCHEMBL16583121 | 0.77 | MAPK1 (0.39) | MAPK1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL25153997 | 0.75 | LCK (0.39) | MAPK1KDM4ECYP2C19LCKGABRP | |
| SCHEMBL16371347 | 0.75 | MRGPRX4 (0.39) | MAPK1KDM4ELCKALDH1A1MAPT | |
| SCHEMBL18662032 | 0.74 | MAPK1 (0.41) | MAPK1KDM4EL3MBTL1LCKLMNA | |
| SCHEMBL31444432 | 0.74 | MAPK1 (0.52) | MAPK1KDM4EL3MBTL1CYP2C19LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665732-B1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2456774-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | MAPK1 2367/4885KDM4E 655/4885L3MBTL1 1721/4885 |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | BACE1, APP, BACE2 | MAPK1 1553/4885KDM4E 1400/4885L3MBTL1 417/4885 |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | MAPK1 2367/4885KDM4E 655/4885L3MBTL1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.